Yu Garden

Yuyuan Garden Lantern Festival Welcomes Consular Officials of 51 Countries in Shanghai to Showcase Oriental Intangible Cultural Heritage to the World

Retrieved on: 
Wednesday, February 8, 2023
Life, Economic development, Foreign, Element, QR, Yuyuan Garden station, Foreign Affairs, Lantern Festival, Pleasure, Classic, Plant, Fosun International, Government, Yue, Gen, The Year of the Rabbit, Culture, Friends, Ministry, Chinese New Year, Beauty, Republic, Classic of Mountains and Seas, Flower, Architecture, Butterfly Lovers, Sea, Digitalization, Social media, Tourism, Film industry, Amusement park, Entertainment, Rabbit, Wolf, Yu Garden

Consular officials of 51 countries in Shanghai visited the Yuyuan Garden.

Key Points: 
  • Consular officials of 51 countries in Shanghai visited the Yuyuan Garden.
  • At the Yuyuan Operatic Garden at Sea, consular officials from various countries in Shanghai gathered to enjoy the beautiful scenery of the Yuyuan Garden.
  • The Yuyuan Garden Lantern Festival hopes to convey the beauty of culture and life, and that beauty is borderless.
  • As a national intangible cultural heritage, the Yuyuan Garden Lantern Festival has been held for the 28th time.

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, December 1, 2022
Risk, SIX Swiss Exchange, Research, Drug development, Security (finance), Cleveland Cultural Gardens, Retirement, Workforce, Coronavirus, Amendment, Forbearance, Clinical trial, Pregnancy, Safety, Pharmacokinetics, IND, Female, BioScience, Center for Drug Evaluation and Research, Sale, Fertilisation, Woman, JGB, Cryptocurrency, Birth control, Pharmaceutical industry, Kissei, Yu Garden

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland December 1, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing novel therapies for womens health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Financial Results for the Third Quarter Ended September 30, 2022
    ObsEva had cash and cash equivalents of $9.7 million at September 30, 2022 compared to $54.7 million at December 31, 2021.
  • The third quarter 2022 financial statements can be accessed in the financial reports section here of the Companys website, or directly here .
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Fosun Makes an Effort to Build the Grand Yuyuan with Oriental Life Aesthetics

Retrieved on: 
Tuesday, September 20, 2022
Happiness, The Bund Finance Center, Orient, Symbiosis, Yuyuan Tourist Mart, Classic of Mountains and Seas, Classic, Fuyou Road Mosque, Life, Growth, Pinnacle, Language, Yu Garden, Ecosystem, Conference, WDCC, Fashion, Fosun International, Health

The masterpiece of Shanghai urban design, the Grand Yuyuan's "Oriental Life Aesthetics Design Demonstration Hub" was officially launched at the event.

Key Points: 
  • The masterpiece of Shanghai urban design, the Grand Yuyuan's "Oriental Life Aesthetics Design Demonstration Hub" was officially launched at the event.
  • Xu Xiaoliang, Co-CEO of Fosun International and Chairmanof Shanghai International Fashion Federation, said: "Design comes from life and serves life.
  • Fosun and Yuyuan are honored to be the developers of the 'Grand Yuyuan'.
  • The "Grand Yuyuan" will be positioned as a global fashion and cultural venue with the charm of oriental life aesthetics.

ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

Retrieved on: 
Wednesday, July 1, 2020
Human reproduction, Huangpu District, Shanghai, Sexual reproduction, Fertility, In vitro fertilisation, Obstetrics, Reproduction, Sperm donation, Yu Garden

As per the partnership agreement, Yuyuan has the exclusive rights to develop and commercialize nolasiban in the Peoples Republic of China (PRC).

Key Points: 
  • As per the partnership agreement, Yuyuan has the exclusive rights to develop and commercialize nolasiban in the Peoples Republic of China (PRC).
  • This submission represents the first milestone in the process to enable a Phase 1 and Phase 2 proof-of-concept study in China.
  • We are excited with todays submission of our pre-IND meeting request for nolasiban which demonstrates the diligence and commitment of our Chinese partner, Yuyuan, said Ernest Loumaye, CEO and Co-Founder of ObsEva.
  • This submission is the first, important step towards establishing the optimal dosing regimen for nolasiban in IVF.